9841 Washingtonian Blvd. Suite 500
4 articles with Leadiant Biosciences
Leadiant Biosciences Is Conducting the Registry Study of Revcovi® Treatment in Patients With ADA-SCID
Leadiant Biosciences, Inc. announced it is conducting the Registry Study of Revcovi® (elapegademase-lvlr) injection 1.6 mg/ml Treatment in Patients with Adenosine Deaminase Severe Combined Immune Deficiency (ADA-SCID).
FDA Approves Revcovi™, a New Enzyme Replacement Therapy Developed by Leadiant Biosciences, for the Treatment of ADA-SCID in Pediatric and Adult Patients
Leadiant Biosciences, Inc. today announced that the Food and Drug Administration (FDA) has granted approval to Revcovi™ (elapegademase-lvlr) injection in the U.S. Revcovi is a new enzyme replacement therapy (ERT) for the treatment of adenosine deaminase severe combined immune deficiency (ADA-SCID) in pediatric and adult patients.
More than a year after Maryland-based Sigma-Tau Pharmaceuticals changed its name to Leadiant Biosciences, the newly-dubbed company is now being associated with a much darker name – that of jailed biotech entrepreneur Martin Shkreli.
Leadiant Biosciences to Collaborate with National Institutes of Health on Therapy in Late-Stage Development for GNE Myopathy
Multi-Center Collaborative Clinical Trial Planned to Test Efficacy of Oral-N-acetyl-D-Mannosamine